Biotech

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the three months ended March 31, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid recorded a net loss and comprehensive loss of $743,636 for the three months ended March 31, 2021, compared to a net loss of $1,320,761 during the three months ended March 31, 2020. The decrease in net loss and comprehensive loss was attributed to the decrease in selling and distribution expenses. Revenues decreased by 5% over the same period last year and gross profit margins decreased to 13% of sales. The Company's sales decreased by approximately $467,000 from the comparative period. During the three-month period ended March 31, 2021, selling and distribution expense decreased by approximately $464,255 largely due to decreased in production (facility costs, quality assurance and lab testing) and production wages which were offset by the government wage subsidy received during the quarter. Administrative expenses decreased by approximately $190,325 predominantly from office, rent and salaries and corporate promotions. The decrease was attributed to a reduction in investor relations activity due to the pandemic and the reduction of corporate salaries from the government wage subsidy.

Naturally Splendid recorded sales of $253,378 during the three months ended March 31, 2021, compared to $720,255 in for three months ended March 31, 2020. The Company's sales decreased by approximately $467,000 from the comparative period which was attributed to decreased sales in its private label bars and bites business.

Cost of Sales during the three months ended March 31, 2021 was $221,587 compared to $593,626 in three months ended March 31, 2020. The Company gross margin percentage decreased to 13%, in the three months ended March 31, 2021.

The Company continued its sales mix with exports of bulk seed and launching its new plant-based products. The bulk hemp seeds sold at a lower gross margin percentage then compared to the plant-based products and private label sales. The Company is now focused on its higher margin products and new commercial opportunities. Gross profits for the three months ended March 31, 2021 was $31,791 (13% of sales) compared to $126,629 (18% of sales) for three months ended March 31, 2020. The best market opportunities for NSE have been both domestic and new international destinations along with Prosnack Natural Foods Inc. private label products.

For the Three Months Ended March 31, 2021For the Three Months Ended March 31, 2020
$$
Statements of Loss Data
Revenue
253,378720,255
Cost of sales
221,587593,626
Gross Profit
31,791126,629
Selling and distribution expenses
(140,166)(604,421)
Administrative expenses
(659,103)(862,864)
Other income(loss) and taxes
(743,636)(1,320,761)
Net income (loss)
(743,636)(1,320,761)
Basic and Diluted Earnings (Loss)
Per Share
(0.00)(0.01)

Naturally Splendid CEO Mr. J. Craig Goodwin reports, "The Company continues to focus on overall plant-based nutrition, health & wellness. The first quarter of 2021 was concentrated on establishing the foundation to our NATERATM Plant Based Foods opportunity. With sales of our premium bars sustaining significant setbacks in 2020 due directly to the pandemic, the Company took this opportunity to transition our primary focus to our NATERATM Plant Based Foods.

The Company has chosen to reduce its contract manufacturing clientele for bars and bites which in the short term has affected gross sales. Instead, the Company will put more emphasis on producing our own Company Brands that have greater margins.

Naturally Splendid continues to establish plant-based opportunities whether that be exports of bulk hemp to South Korea that has seen a recent resurgence, manufacturing bars and bites formulated for the sports and active lifestyle market, advancing the science of CavaltinibTM, the target drug approved by Health Canada for a phase 2 clinical trial for COVID, or driving business of our NATERATM Plant Based Foods through multiple distribution channels. Although diverse opportunities, the common denominator of these opportunities is all rooted in plant-based ingredients and products.

In particular, NATERATM Plant Based Foods are at the forefront of our efforts. In this regard, we have invested significantly in our NATERATM Plant Based Foods inventory and have established a comprehensive distribution network that covers Canada coast to coast. Distributors include CANEX Foods, Sysco, Gordon Food Service, Intercity Packers Meat and Seafood, Georgia Main Food Group, and others. This network of distributors provides access to thousands of clients across most every distribution channel including chain and independent retail stores as well as chain restaurants and individual locations.

The Company is leveraging our distributor network and developing relationships in the food service / restaurant channels for our NATERATM Plant Based Food line. With significant COVID restrictions being placed on the restaurant industry in particular, sales in this channel have been hindered. However, governments and health authorities have begun the process of relaxing many of these restrictions and we are confident the groundwork laid in this area will begin to provide a recurring revenue stream and we look forward to providing timely updates in this regard.

Efforts have been expended establishing new e-commerce strategies to support multiple online marketing initiates and our e-commerce sites are now operational. Our complete line of NATERATM Plant Based Foods including Plant-Based Burgers; Breaded Cutlets (Schnitzel); Garlicky Chick-Un Kiev; Sweet Chili Chick-Un Tenders; Seasoned Chick-Un Tenders; Chick-Un Nuggets; Chick-Un Patties; Crispy Fish-Un Fillets; Garlicky Chick-Un Bites and Cheesy Chick-Un Bites, are now available online.

Transitioning product mixes is not without challenge. However, we are confident the decisions that have been made to promote our own Company Brands and establishing NATERATM Plant Based Foods as our feature line will provide the foundation to growing shareholder value. We look forward to providing updates in a timely manner."

Naturally Splendid's financial statements can be viewed at: www.SEDAR.com

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-465-0548 (ext. 105)

On Behalf of the Board of Directors

Mr. J. Craig Goodwin

CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/649840/Naturally-Splendid-Reports-First-Quarter-Results-for-2021

News Provided by ACCESSWIRE via QuoteMedia

Naturally Splendid Enterprises

Naturally Splendid Enterprises


Keep reading...Show less

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

-- Viral Vector Facility Further Strengthens Vertical Integration of Kite's Global CAR T-cell Therapy Manufacturing Network, Supports Growing Demand of Company's Blood Cancer Treatments --

-- Kite is the Only Cell Therapy Company with In-House Viral Vector Manufacturing Capabilities for Both Commercial Products and Clinical Trials --

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today that study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ inhibits and also promotes the reversal of mechanisms known to play a role in the occurrence and development of fibrotic CVD. The data were presented by its research collaborators from Houston Methodist DeBakey Heart & Vascular Center at The Annual Scientific Meeting of the Heart Failure Society of America ("HFSA2022").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Continues Strategic Expansion in US Hotel Sector After Receiving Purchase Order from Virgin Hotels Chicago to Become Supplier of Gummy Products for Guest Room Mini-Bars

The Gummy Project Continues Strategic Expansion in US Hotel Sector After Receiving Purchase Order from Virgin Hotels Chicago to Become Supplier of Gummy Products for Guest Room Mini-Bars

  • The Gummy Project's Peachy Bees and Watermelon Sharks expected to be featured for sale in all 250 guest rooms at the Virgin Hotel Chicago.
  • Purchase order continues The Gummy Projects strategic expansion in the Canadian and US Hotel sector.

The Gummy Project (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce that it has received a purchase order from the Virgin Hotels Chicago to become a supplier of gummies for each of the hotel's 250 guest room mini-bars.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022

  • Final analyses from the U-ACHIEVE Phase 3 maintenance study of RINVOQ ® (upadacitinib) in moderately to severely active ulcerative colitis
  • Data highlighting symptomatic and endoscopic outcomes, delayed subcutaneous responders and predictors of response in patients receiving risankizumab (SKYRIZI ® ) for use in moderate to severe Crohn's disease *
  • Data from the Phase 3 study U-EXCEL evaluating the efficacy and safety of upadacitinib (RINVOQ ® ) as induction therapy for use in adults with moderately to severely active Crohn's disease *
  • A total of 17 abstracts, including seven oral presentations, reinforce AbbVie's commitment to research into developments that could help advance standards of care for patients living with inflammatory bowel disease (IBD)

ABBVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI ® ) in Crohn's disease and upadacitinib (RINVOQ ® ) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. In total, ABBVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).

"With two decades of world-class science and an unwavering commitment to patients, we continue to advance research within our robust gastro portfolio with the goal of positively impacting the lives of people living with inflammatory bowel disease," said Chiedzo Mpofu, MBChB, Ph.D., vice president, Global Medical Affairs, Immunology, AbbVie. "Our data at UEG Week 2022 reinforce our dedication to innovation and partnership with the gastroenterology community to help address a wide range of patient needs and investigate diverse solutions to help advance standards of care for IBD patients."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Issues Corporate Update

Sirona Biochem Issues Corporate Update

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (" Sirona ") announces the release of a corporate update which highlights the company's recent team meeting in France, the current pipeline, and the latest deal structure.

With the success of the licensing deal with AbbVie, the company needs to prepare for its next phase of growth.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today that an abstract submitted by its international research collaborators from Houston Methodist DeBakey Heart & Vascular Center was accepted for poster presentation at The Annual Scientific Meeting of the Heart Failure Society of America ("HFSA2022") to be held in person September 30th to October 3rd, 2022 in Washington, DC.

The poster will be presented for general viewing within the "Basic and Translational Science" category of the HFSA2022 Scientific Programme on September 30, 2022, from 6:15 – 6:30 PM EDT.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×